Abstract How lymphocyte counts relate to treatmentresponse in patients with ANCA-associated vasculitis (AAV) is controversial, and data on short-term variability of lymphocyte counts are lacking. Retrospective single center evaluation of disease activity and lymphocyte counts in patients with AAV, and of lymphocyte counts in kidney transplant-recipients, were done; both at the University Hospital Basel, Switzerland. Twenty-three patients with AAV were included. Remission was achieved in all patients. Ten patients experienced a relapse after a median of 66 weeks (range 15-189 weeks). Median lymphocyte counts at diagnosis were signiWcantly higher than at remission (1.38 £ 10 9 /L vs. 0.99 £ 10 9 /L; P = 0.007). By contrast, median lymphocyte counts at remission and relapse did not diVer signiWcantly. However, intra-individual variability of lymphocyte counts early after diagnosis was high [median lymphocyte variability-range during the Wrst 3 weeks of treatment 1.57 (range 0.27-3.95), n = 17]. This variability was not speciWc to patients with AAV, but was also observed in patients after kidney transplantation [variability of 1.76 (range 0.74-3.95, n = 31)]. The signiWcantly higher median lymphocyte counts at diagnosis of AAV make lymphocyte counts a valuable surrogate for the treatment-eYciency in clinical studies. By contrast, on a patient-level, variability of lymphocyte counts impedes meaningful interpretation of individual measurements.
Introduction
Therapeutic options for severe AAV are limited, and therapy-mostly cyclophosphamide (CYC)-based-remains a balancing act between disease-and treatment-related morbidity and mortality [1, 2] . Factors predicting treatmentresponse would hence be important.
Lymphocytes, both of the T-and B-cell lineage, are thought to be involved in the pathogenesis of AAV [3] [4] [5] [6] . How circulating lymphocyte counts relate to disease activity, however, remains controversial. One study reported that treatment-induced lymphopenia (·0.5 £ 10 9 /L) is associated with a high likelihood to achieve sustained remission [3, 7] . By contrast, another group suggested that, analogous to patients with systemic lupus erythematodes, lymphopenia in AAV reXects disease activity, with lymphocyte counts actually increasing in patients achieving remission [8, 9] . While the reason for these contradictory Wndings remain unclear, neither study has taken into account short-term variability of lymphocyte counts and how this might impact study results.
Here, we investigated how in AAV-patients (1) median lymphocyte counts relate to disease activity on a population level, and (2) assessed, in these same individuals, shortterm lymphocyte count variability.
Patients and methods

Study populations
After obtaining approval by the institutional review board, disease activity and lymphocyte counts in patients with AAV (diagnosed between 1/1992 and 12/2007), and lymphocyte counts in kidney transplant-recipients (transplanted within the living-donor program between 1/2004 and 12/ 2006) were retrospectively assessed in patients treated at the University Hospital Basel, Switzerland. Medical charts from all patients with a deWnite diagnosis of AAV were reviewed to obtain demographic, clinical and laboratory data.
Diagnosis and follow-up of AAV AAV was diagnosed according to American College of Rheumatology (ACR) criteria [10] , the Birmingham Vasculits Activity Score (BVAS) [11] was calculated initially and for every subsequent visit. 
Outcome parameters
Remission of AAV was deWned as complete absence of clinical symptoms and a daily prednisone-dose ·7.5 mg, according to published criteria [12] . Relapse was deWned as de novo disease activity according to the BVAS [11] .
Statistical analysis
Discrete variables are expressed as counts (percentage), continuous variables as medians and ranges. Frequency comparison was done by Chi-square test. Two-group comparison of normally distributed data was performed by paired or unpaired Student's t test. For not normally distributed 
Results
Patient's characteristics
Of the 33 AAV patients identiWed, 23 (70%) were included in the analysis, 10 patients (30%) had to be excluded from the analysis because of missing data, being lost during follow-up, or due to concurrent diagnoses other than AAV necessitating immunosuppressive therapy. Wegener's granulomatosis was diagnosed in 18/23 patients (78%), ChurgStrauss Syndrome in 3/23 patients (13%), two patients had AAV not otherwise classiWed. A total of 14/23 patients were female (61%), the median age at diagnosis was 55 years (range, 22-77 years). Relevant baseline characteristics of the AAV study population are summarized in Table 1 . Median BVAS at diagnosis was 13 (range 6-35). Sixteen out of twenty-three patients had CYC as part of their induction therapy. Median CYC dose-to-remission was 13.5 g (range, 1.5-76.5 g). All 23 patients (100%) achieved remission [median time-to-remission, 26 weeks (range 10-87 weeks)], 10/23 patients (43%) experienced a relapse [median timeto-relapse: 66 weeks (range 15-189)]. The control-cohort of kidney transplant-recipients (n = 31), transplanted consecutively between 2004 and 2006) received immunosuppressive regimens containing glucocorticoids, mycophenolate mofetil, and tacrolimus. Ten/31 (33%) transplant-recipients were female; the median age at transplantation was 50 years (range, 19-68 years).
Lymphocyte counts
Lymphocyte counts were analyzed (1) cross-sectional (i.e., on a population level) at diagnosis and in remission, and (2) longitudinally (i.e., intra-individually) during the Wrst 3 weeks after diagnosis. On a population level, median lymphocyte counts at diagnosis [Wrst measurement 1.38 £ 10 9 L (range: 0.5-3.11)] were signiWcantly higher than median lymphocyte counts in remission [Wrst measurement in remission, 0.99 £ 10 9 L (range, 0.17-3.1), P = 0.007] (Fig. 1) . Relapsing and non-relapsing patients had similar lymphocyte counts both at diagnosis and in remission [median lymphocyte counts at diagnosis, relapsing patients: 1.54 (range 0.77-3.11), non-relapsing patients: 1.34 (range 0.5-2.56), P = 0.15, median lymphocyte counts in remission, relapsing patients: 0.94 (range 0.17-3.1), nonrelapsing patients: 0.99 (range 0.41-2.82), P = 0.88]. Timeto-remission was independent of initial lymphocyte counts (P = 0.8, Cox regression).
However, serial lymphocyte counts early after diagnosis [deWned here as ¸4 (range 4-17) measurements during the Wrst 3 weeks after diagnosis; available in n = 17 AAVpatients] revealed a high intra-individual variability of lymphocyte counts, even if measured in very short (daily) intervals [median intra-individual variability-range; 1.57 Fig. 1 Lymphocyte counts at diagnosis, in remission and at relapse of AAV. Boxes denote median and interquartile ranges; whiskers denote ranges Fig. 2 Variability of serial lymphocyte counts during the Wrst 3 weeks of therapy in patients with AAV (left panel) and in patients after kidney transplantation (right panel). Boxes denote median and interquartile ranges; whiskers denote ranges (range 0.27-3.599)]. The lymphocyte count variability in patients with AAV was compared to the variability in a cohort of kidney transplant-recipients during the Wrst 3 weeks after transplantation (n = 31, 4-21 measurements). The median lymphocyte count at transplantation was 0.95 £ 10 9 /L (range, 0.12-2.8), the median intra-individual variability-range 1.76 (range 0.74-3.95). Variability of lymphocyte counts in AAV-patients and transplant-recipients was similar, excluding an AAV-speciWc phenomenon (P = 0.48) (Fig. 2) .
Discussion
The key observations of this study are that (1) in patients with AAV median lymphocyte counts on a cohort level are higher at presentation than in remission, and (2) in a given AAV-patient intra-individual short-term variability of lymphocytes is making their value as an indicator of treatmenteYciency questionable. The major limitations of our study are its retrospective design, and the small number of patients that were studied. Despite these limitations, the range of the observed short-term lymphocyte count variability-which is essentially unaVected by the study design-may have implications possibly extending beyond the Weld of clinical AAV-research.
In the context of AAV, our data-on a cohort level-are in-line with the plausible notion stemming from a relatively large study stating that lymphocyte counts inversely associate with sustained remission [7] . However, by combining cohort-derived data and analyses in individual patients, our results indicate that the value of individual lymphocyte counts in reXecting treatment-eYciency is limited.
While for now remaining a provocative hypothesis, short-term (day-by-day!) variability of lymphocyte counts may also inXuence clinical decision making when judging immuno-competence, e.g., in patients infected with HIV or in transplant-recipients.
In summary, our study establishes a surprising shortterm variability of lymphocyte counts both in patients with AAV, and in a heterogeneous group of kidney transplantrecipients. Larger, ideally prospective studies integrating short-term variability of peripheral lymphocyte counts and disease activity are needed to more deWnitely establish the value of lymphocyte counts as biomarkers for the treatment-eYciency in patients suVering from AAV.
